Zenas BioPharma, Inc.
Description
Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody for various indications, including immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. The company also develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; ZB001, an anti-insulin-like growth factor-1 receptor monoclonal antibody; and ZB005, an anti-active complement component 1s monoclonal antibody. Zenas BioPharma, Inc. was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is based in Waltham, Massachusetts.
About
CEO
Mr. Leon Oliver Moulder Jr., M.B.A.
Employees
114
Instrument type
ETF
Sector
Healthcare
Industry
Biotechnology
MIC code
XNMS
Address
North Building, Waltham, MA 02451, United States
×
![Enlarged Chart]()
Oscillators
No data available
Summary
No data available
Moving Averages
No data available
Earnings
| Date | Estimate EPS | Actual EPS | Difference | % Surprise |
|---|---|---|---|---|
| Nov 12, 2024 | -9.33 | -5.02 | 4.31 | -46.20% |
Earnings estimate
| Number of analysts | — | — | — | — |
|---|---|---|---|---|
| Average estimate | — | — | — | — |
| Low estimate | — | — | — | — |
| High estimate | — | — | — | — |
| Last year EPS | — | — | — | — |
[stock_revenue_estimate]
Error: Invalid Growth Estimates JSON format.
Income statement
| 2023 | 2022 | |
|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 |
| Total reported revenue | 50.00M | — |
| Cost of revenue | — | — |
| Gross profit | — | — |
| Operating expense | ||
| Research & development | 60.03M | 61.69M |
| Selling general and admin | 17.11M | 13.51M |
| Other operating expenses | — | — |
| Operating income | -27.15M | -75.20M |
| Non operating interest income | ||
| Income | — | — |
| Expense | — | — |
| Other income expense | -9.68M | -44.08M |
| Pretax income | -36.82M | -119.28M |
| Tax provision | 301,000 | — |
| Net income | -37.12M | -119.28M |
| Basic EPS | -2.88 | -9.26 |
| Diluted EPS | -2.88 | -9.26 |
| Basic average shares | 12.88M | 12.88M |
| Diluted average shares | 12.88M | 12.88M |
| EBITDA | -17.03M | -60.85M |
| Net income from continuing op. | -37.12M | -119.28M |
| Minority interests | — | — |
| Preferred stock dividends | — | — |
Balance sheet
| 2023 | 2022 | |
|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 |
| Total assets | 68.18M | 74.58M |
| Current assets | ||
| Cash | 56.86M | 67.21M |
| Cash equivalents | — | — |
| Cash and cash equivalents | 56.86M | 67.21M |
| Other short term investments | — | — |
| Accounts receivable | — | — |
| Other receivables | — | — |
| Inventory | — | — |
| Prepaid assets | — | — |
| Restricted cash | — | — |
| Assets held for sale | — | — |
| Hedging assets | — | — |
| Other current assets | 2.95M | 1.24M |
| Non current assets | ||
| Properties | 1.01M | 1.80M |
| Land and improvements | — | — |
| Machinery furniture equipment | — | — |
| Construction in progress | — | — |
| Leases | — | — |
| Accumulated depreciation | — | — |
| Goodwill | — | — |
| Investment properties | — | — |
| Financial assets | — | — |
| Intangible assets | — | — |
| Investments and advances | — | — |
| Other non current assets | 1.57M | 212,000 |
| Total liabilities | 293.90M | 266.87M |
| Current liabilities | ||
| Accounts payable | 5.40M | 5.82M |
| Accrued expenses | 11.88M | 15.11M |
| Short term debt | 556,000 | 715,000 |
| Deferred revenue | — | — |
| Tax payable | 301,000 | — |
| Pensions | 5.12M | 4.33M |
| Other current liabilities | — | — |
| Non current liabilities | ||
| Long term debt | 20.56M | 812,000 |
| Provision for risks and charges | — | — |
| Deferred liabilities | — | — |
| Derivative product liabilities | — | — |
| Other non current liabilities | — | — |
| Shareholders equity | ||
| Common stock | — | — |
| Retained earnings | -230.40M | -193.28M |
| Other shareholders equity | 37,000 | -41,000 |
| Total shareholders equity | -225.72M | -192.29M |
| Additional paid in capital | 4.65M | 1.03M |
| Treasury stock | — | — |
| Minority interest | — | — |
Cash flow statement
| 2023 | 2022 | |
|---|---|---|
| Operating Activities | ||
| Net Income | -37.12M | -119.28M |
| Depreciation | 113,000 | 78,000 |
| Deferred Taxes | — | — |
| Stock-Based Compensation | 3.50M | 737,000 |
| Other Non-Cash Items | 11.03M | 31.58M |
| Accounts Receivable | — | — |
| Accounts Payable | -418,000 | 1.09M |
| Other Assets & Liabilities | -714,000 | -717,000 |
| Operating Cash Flow | -23.62M | -86.51M |
| Investing Activities | ||
| Capital Expenditures | -17,000 | -198,000 |
| Net Intangibles | — | -2.00M |
| Net Acquisitions | — | — |
| Purchase of Investments | — | — |
| Sale of Investments | — | — |
| Investing Cash Flow | -17,000 | -198,000 |
| Financing Activities | ||
| Long-Term Debt Issuance | 20.00M | — |
| Long-Term Debt Payments | — | — |
| Other Financing Charges | — | — |
| Financing Cash Flow | 20.00M | 59.39M |
| Other Cash Details | ||
| End Cash Position | 56.94M | 67.30M |
| Income Tax Paid | — | — |
| Interest Paid | — | — |
| Free Cash Flow | -30.55M | -67.85M |
Error: Invalid format in Holders JSON file.
Article
Zenas BioPharma Announces Key 2024 Accomplishments and 2025 Business Objectives to Support the Global Development and Commercialization of Therapies for Autoimmune Diseases
- Advancing Phase 2 and Phase 3 trials of obexelimab, a unique CD-19 x FcγRIIb inhibitor of B cell function- -Topline results from Phase 2 Trial in Relapsing Multiple Sclerosis (MoonStone) expected in third quarter 2025- -Topline results from pivotal Phase 3 Trial in Immunoglobulin G4-Related Disease (INDIGO) expected year-end 2025- - Enrollment of Phase 2 Trial in Systemic Lupus Erythematosus (SunStone) expected to be completed in 2025- - Out-licensed greater-China anti-IGF-1R Thyroid Eye Disease programs to Zai Lab - WALTHAM, Mass., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of therapies for autoimmune diseases, today announced its 2024 accomplishments, outlined its key business objectives for 2025 and announced preliminary unaudited cash balance as of year-end 2024.
Feb 5, 2025
Article
Zenas BioPharma to Present at the Guggenheim SMID Cap Biotech Conference
WALTHAM, Mass., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative immunology-based therapies, today announced management's fireside chat presentation at the Guggenheim SMID Cap Biotech Conference on Wednesday, February 5, 2025, at 3:00 p.m. ET.
Jan 28, 2025
Article
Zenas BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
-Completed initial public offering, raising $258.7 million in gross proceeds, to fund the expanded clinical development of lead product candidate, obexelimab, and support company growth strategy-
Nov 12, 2024
